NR1H4 and metabolic dysfunction-associated steatohepatitis: Furthermore, a recent phase II clinical trial showed that INT-747, a potent agonist of bile acid farnesoid X receptor, could improve histological activity and reduce fibrosis in adult patients with non-alcoholic steatohepatitis [32], indicating bile acid receptors may be a potential therapeutic target for liver disease management in DHF.